TELMISARTAN MARKET ANALYSIS

Telmisartan Market Size and Trends

Global telmisartan market is estimated to be valued at USD 4.20 Bn in 2024 and is expected to reach USD 5.41 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 3.7% from 2024 to 2031.

To learn more about this report, Request sample copy

Global telmisartan market growth is driven by increasing demand for effective drugs for treatment of hypertension. Telmisartan is mainly prescribed for the primary treatment of hypertension and can effectively lower blood pressure levels. It is also used to reduce the risk of cardiovascular events for patients who cannot tolerate ACE inhibitors. Favorable government policies for prevention and control of hypertension along with rising healthcare spending can also drive the market growth. However, availability of generic substitutes once patents expire can hamper the market growth.

Rising prevalence of hypertension

Rising prevalence of hypertension can drive the market growth. According to the World Health Organization, hypertension is one of the leading causes of preventable death worldwide as it significantly raises the risks of heart disease and stroke. High blood pressure increases the workload of the heart which can eventually lead to damage of key organs and vessels in the body. If uncontrolled for many years, it progressively impairs the function of arteries and major organs. According to the data from National Health Surveys, hypertension affects over 1.13 billion people worldwide. Its occurrence varies across countries and regions depending on lifestyle habits and risk factors prevalent in different populations. Rapid aging of populations and sedentary jobs and unhealthy dietary patterns linked to urbanization contribute to prevalence of hypertension. More people are now consuming calorie-dense processed foods high in sodium, sugar, and unhealthy fats. At the same time, physical activity levels have fallen sharply in both developed and developing nations. These lifestyle transitions have contributed significantly to the hypertension epidemic. Considering the enormity of the problem and its severe ramifications, it has become imperative for healthcare systems globally to step up screening as well as provide effective long-term treatment solutions. Telmisartan has established itself as one of the most attractive medical options due its strong efficacy and tolerability profile. Its widespread adoption by physicians can boost its demand. For instance, as per a joint study by World Health Organization (WHO) and Imperial College London,  the number of adults aged 30–79 years with hypertension has increased from 650 million to 1.28 billion over the past three decades. Published in The Lancet Journal, the study underscores that nearly half of these individuals were unaware of their condition, highlighting significant gaps in diagnosis and treatment.

To learn more about this report, Request sample copy

Growing awareness about telmisartan therapy

Global telmisartan market growth is driven by growing awareness about its effectiveness and safety in the treatment of hypertension. Telmisartan is an angiotensin receptor blocker (ARB) that is widely prescribed by cardiologists and vascular physicians for management of high blood pressure. It is known to be well-tolerated with minimal side effects as compared to other anti-hypertensive drugs. For instance, as per the report published by the American Heart Association in 2021, long term use of telmisartan lowered the risk of stroke and dementia in elderly hypertensive patients. As per a meta-analysis published by European Journal of Preventive Cardiology in 2020, telmisartan is superior over other ARBs in reducing cardiovascular and all-cause mortality. Growing evidence of telmisartan's organ protective qualities beyond blood pressure control has increased physician's preference for the drug. Telmisartan has also gained traction due to its affordability and once-daily dosing regimen. This ensures high patient compliance which is crucial for effective management of lifelong conditions like hypertension. According to the data from World Health Organization in 2022, non-adherence to medication is a major public health challenge especially in developing nations. The simplicity and low cost of telmisartan therapy makes it suitable for improving access and adherence to treatment in resource-constrained settings.